AIDS 2022: The latest on long-acting HIV prevention and treatment
Elri Voigt summarises some of the latest developments on long-acting therapies for HIV presented at the 2022 International AIDS conference.
Elri Voigt summarises some of the latest developments on long-acting therapies for HIV presented at the 2022 International AIDS conference.
In 2021, HIV was successfully suppressed in the bodies of around 63% of the close to eight million people living with HIV in South Africa. This is according to recent outputs from Thembisa, the leading mathematical model of HIV in South Africa. With the help of some graphs, Spotlight editor Marcus Low unpacks this and other key model outputs.
There is no time to waste in planning the South African rollout of cabotegravir (CAB LA), the long-lasting antiretroviral injection approved for use in the United States in December 2021, say local health experts.
HIV medicines for children often taste bitter, pills are large, and for many children there is a lot of medication to take. This makes it hard to take treatment as prescribed. Tiyese Jeranji looks at the challenges with currently available HIV medicines for children, what innovations are in the pipeline, and how HIV treatment is being tailored to suit the needs of children.
The U=U campaign is based on a simple message – an undetectable viral load in people living with HIV equals an untransmissible virus. The U=U campaign, argues Mandisa Dukashe, has the power to motivate people living with HIV to adhere to ARVs, achieve viral suppression, and subsequently lead long and healthy lives while preventing HIV transmission to sexual partners and their babies.
Government is resuscitating its plans for a state-owned pharmaceutical company and is preparing to announce a new partner in the project. Catherine Tomlinson investigates.
By Marlise Richter – The US President’s Emergency Plan for AIDS Relief (PEPFAR) should end its anti-prostitution pledge.